January 31st 2023
The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.
Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.
The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.
An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.
Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.
Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.
Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.
Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.
Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.
In this program, our expert panel discusses several topics pertaining to type 1 diabetes, including screening and diagnosis, current and emerging treatments, and the role of clinicians in early testing and patient education.
An expert endocrine clinical pharmacist and nurse practitioner discuss clinical trial data on how inhaled insulin affects glucose management in T1D and T2D.
Drs Diana Isaacs and Natalie Bellini share the FDA-approved patient populations for inhaled insulin use to manage diabetes, as well as who would not be a good candidate.
Experts examine the use of Technosphere insulin, how it is delivered to the body, and the qualities of an ideal rapid-acting insulin analog in type 1 and type 2 diabetes.
Drs Diana Isaacs and Natalie Bellini discuss the limitations of injectable insulins in achieving time-in-range and glucose targets in type 1 and type 2 diabetes.
Expert health care practitioners review the different types of insulin formulations available for people with T1D or T2D, including regular and rapid-acting.